⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946852 | 1.00 | — | — | |
| SCHEMBL689008 | 1.00 | — | — | |
| SCHEMBL23097874 | 0.76 | — | — | |
| SCHEMBL22677261 | 0.76 | — | — | |
| SCHEMBL29335541 | 0.76 | — | — | |
| SCHEMBL25955534 | 0.76 | — | — | |
| SCHEMBL18630353 | 0.74 | — | — | |
| SCHEMBL22931432 | 0.72 | — | — | |
| SCHEMBL21965060 | 0.72 | — | — | |
| SCHEMBL16084910 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3406609-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LTD (GB) | 2024-06-26 | — | — | EP | disclosed |
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146513-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20220216426-A1 | NITROGEN-CONTAINING COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2021202977-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-11028087-B2 | 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2021-06-08 | — | — | US | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020112937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| US-10174032-B2 | Heterocyclic compound classes for signaling modulation | SIGNALRX PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180130853-A1 | DISPLAY COMPONENT AND MANUFACTURING METHOD THEREFOR | GUANGZHOU CHINARAY OPTOELECTRONICS MATERIALS LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| WO-2017140778-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-08-24 | — | — | WO | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2423207-A2 | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| EP-2423208-A1 | Pharmaceutically active compounds as Axl inhibitors | Lead Discovery Center GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010050461-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | 田辺三菱製薬株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009151683-A2 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | LINK MEDICINE CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-1696501-B1 | Electrolyte for a lithium battery and a lithium battery comprising the same | SAMSUNG SDI CO LTD (KR) | 2007-12-05 | — | — | EP | disclosed |